BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 12886872)

  • 1. The global role of irinotecan in the treatment of lung cancer: 2003 update.
    Langer CJ
    Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):30-40. PubMed ID: 12886872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan in advanced lung cancer: focus on North American trials.
    Langer CJ
    Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):17-28. PubMed ID: 15255164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
    Masuda N
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging world role of irinotecan in lung cancer.
    Langer CJ
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):15-21. PubMed ID: 11497227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.
    Lara PN; Chansky K; Shibata T; Fukuda H; Tamura T; Crowley J; Redman MW; Natale R; Saijo N; Gandara DR
    Cancer; 2010 Dec; 116(24):5710-5. PubMed ID: 20737417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoradiation in locally advanced non-small cell lung cancer.
    Bonomi P; Shirazi W
    Cancer Treat Res; 2001; 105():171-88. PubMed ID: 11224987
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: use patterns among American medical oncologists 2000-2006.
    Green MR; Dowlati A; Yellamraju L; Daniels L; Willey J; Andrews M; Leff R
    J Thorac Oncol; 2007 Oct; 2(10):953-6. PubMed ID: 17909359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan.
    Langer CJ
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):19-24. PubMed ID: 11221017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan plus cisplatin in small-cell lung cancer.
    Sandler A
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):39-43. PubMed ID: 12375800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.
    Green MR
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):17-21. PubMed ID: 12170447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan therapy for small-cell lung cancer.
    Sandler A
    Oncology (Williston Park); 2002 Apr; 16(4):419-25, 428, 433; discussion 433-4, 437-8. PubMed ID: 12017533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination chemotherapy in the treatment of inoperable non-small cell lung cancer].
    Masuda N
    Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():379-83. PubMed ID: 9369911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
    Calvo AR; Belani CP
    Cancer Treat Res; 2001; 105():189-227. PubMed ID: 11224988
    [No Abstract]   [Full Text] [Related]  

  • 15. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
    Rigas JR
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):15-20. PubMed ID: 11441410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New state of the art in small-cell lung cancer.
    Tamura T
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):8-10. PubMed ID: 11221023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
    Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
    J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs for small-cell lung cancer.
    Murray N
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 9):38-42. PubMed ID: 9330407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.
    Natale RB
    Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):22-6. PubMed ID: 12886870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Developed new agents for lung cancer].
    Kato Y; Saijo N
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):218-23. PubMed ID: 11904983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.